Institute of Cancer Research, United Kingdom
180
32
54
61
Key Highlights
Risk & Performance
Pipeline Risk Assessment
Pipeline Risk Assessment
Based on historical performance
Moderate Risk
Score: 50/100
5.6%
10 terminated/withdrawn out of 180 trials
85.9%
-0.7% vs industry average
16%
28 trials in Phase 3/4
23%
14 of 61 completed trials have results
Key Signals
Enrollment Performance
Analytics
Activity Timeline
Global Presence
Clinical Trials (180)
Investigating SX-682 in Combination With Apalutamide in Metastatic Castration-resistant Prostate Cancer
Role: lead
Investigating the Combination of Bexmarilimab and Nivolumab in Solid Tumours, Melanoma and NSCLC
Role: lead
KORTUC Phase II - Intra-tumoural Radiation Sensitizer in Patients With Locally Advanced/Recurrent Breast Cancer
Role: lead
International Penile Advanced Cancer Trial (International Rare Cancers Initiative Study)
Role: lead
Study of Ibrutinib + CD20 Antibody and Venetoclax in Patients With Untreated Mantle Cell Lymphoma
Role: collaborator
5G-EMERALD: Amivantamab in Malignant Brain Tumours
Role: lead
UK Genetic Prostate Cancer Study: Epidemiology and Molecular Genetics Studies
Role: lead
Patient and Provider Perspectives on Genetic Risk Profiling
Role: collaborator
Understanding the Genetic and Biological Factors That Influence Cancer Treatment Response and Resistance in Patients With Advanced Solid Tumours Through Sample Analysis
Role: lead
SBRT Alone or Followed by Niraparib for Oligometastases or Oligoprogression in Ovarian Cancer Following PARPi Therapy
Role: lead
PARa-aOrtic LymphAdenectomy in Locally Advanced Cervical Cancer
Role: collaborator
ASTEROID: A Trial of ASTX660 in Combination With Pembrolizumab
Role: lead
Dose Escalation Study With Expansion to Evaluate Safety, Tolerability, Pharmacokinetics & Pharmacodynamics of CCT3833
Role: collaborator
Combination Study of Guadecitabine/ASTX727 and Pembrolizumab
Role: collaborator
POTENT - Tepotinib in Combination With Pembrolizumab in NSCLC
Role: lead
Pembrolizumab and Palliative Radiotherapy in Lung
Role: collaborator
The BALANCE Study: BlAck and Mixed Men's Lived Experience With Prostate cANCEr-Diversity in Prostate Cancer PROMS Study
Role: lead
PEmbrolizumab Combined With Chemoradiotherapy in Squamous Cell Carcinoma of the Head and Neck
Role: collaborator
Population Based Germline Testing for Early Detection and Prevention of Cancer
Role: collaborator
Transcriptional Responses as an Indicator of Individualised Responses to Radiation Effects (RTGene 2)
Role: lead